Evgen Pharma Share Discussion Threads

[cl0ckw0rk0range] 25/3/2019 08:16

Superb RNS

[blakeysangel] 25/3/2019 08:05

What a great Monday morning😀 no work today and great results. I still stand by my belief this would benefit as a first line treatment with tamoxifen. Having an extra portion of broccoli to day to celebrate!! 😀😀

[l0ngterm] 25/3/2019 07:57

Fantastic news!!!

[nobbygnome] 25/3/2019 07:55

Wow! 20k bought pre market at 29p!

[nobbygnome] 25/3/2019 07:47

Sadly because of my schedule today, I won't be able to dial into the conference call. For those who do questions about a possible deal is the key issue IMHO.

[nobbygnome] 25/3/2019 07:41

Up 25% pre market.....

[nobbygnome] 25/3/2019 07:40

I'm very confident they will be able to do a deal. Pharma are desperate for drugs which have positive clinical data. Approval should be possible with a relatively small and cheap phase III trial.

[letmepass] 25/3/2019 07:40

All bio companies today. EVG, ONC OVB

[purple11] 25/3/2019 07:36

that's the problem here.either that or a placing.theres no cash left.would they be able to do a placing for enough to continue this?

[nobbygnome] 25/3/2019 07:31

Yes one would hope they have had commercial discussions already and have some companies lined up. A prompt deal is vital now.

[sicilian_kan] 25/3/2019 07:23

So where next. The below is fairly clear. Publish the results and do a deal. Note the business development activity is ongoing.

"We now look forward to submitting the data to the 2019 ESMO Congress in Barcelona, a key event in terms of disseminating the results to the clinical community and supporting our ongoing business development activity."

[timbo003] 25/3/2019 07:23

>>>Blakeysangel,

You must be delighted, as this should reinforce your conviction that sulforaphane is having some effect in your own case. Time to double up on the Broccoli sprouts 😃😃

[ohisay] 25/3/2019 07:20

Great news for everybody - investors and patients alike .

[sicilian_kan] 25/3/2019 07:18

Excellent results. Glad I didn’t top slice on this one. It’s going to be a good day here...

[dave444] 25/3/2019 07:15

Excellent results

[timbo003] 25/3/2019 07:15

That result has certainly exceeded my expectations

Note: the Web cast later today will take questions from private shareholders

Private shareholders with questions should email them to
[e-mail]
during or after the webcast; the questions will be collated for inclusion in the webcast.

[nobbygnome] 25/3/2019 07:06

So there we have it; the drug will proceed on to a phase III trial in earlier patients. There were a further 7 patients who responded in the second part of the trial so that is very encouraging as it is a tough end point in these patients.

Well done Evgen! Onwards and upwards....

[ayl30] 25/3/2019 07:05

Rns looks good

[dave444] 24/3/2019 18:50

Here's hoping for great news preferably tomorrow

[nobbygnome] 24/3/2019 14:36

Two reasons. One it makes it easier to recruit patients for the trial because you are not limited to one SOC drug and two it means they will get a broader label (assuming the phase III is done in the same way).

[l0ngterm] 23/3/2019 21:31

Unless we are discussing SfX-01 as being a treatment for cancer standalone, which I don't believe it is. The drug is an enabler IMHO..

[l0ngterm] 23/3/2019 21:30

sfx-01 has demonstrated in the lab that it works well with hormone replacement drugs that are SERM. Tamoxifen being the obvious or the most obvious SERM treatment. So each arm has its own MOA to treat hormones. So why have two, in fact possible just one SERM treatment arm against two other drugs that don't have the same MOA?

[nobbygnome] 23/3/2019 20:55

The drug is just being used with SOC treatments so is not really 3 different arms. It isn't ethical not to use SOC and it is common that multiple possible SOC drugs are included.

So really I am not quite sure what your point is but for the trial to be successful I am pretty sure there has to be a 20% response rate in the 47 patients so 9 responders as defined by the trial protocol.

[l0ngterm] 23/3/2019 20:40

After a quick review, here are some questions for the board.1) as the trial has three arms, does this mean that a clinical benefit rate of 20% in one arm will suffice. 2) two elements of the trial focus on (SERM) treatments. Which have been shown in the lab to highly successful. Why introduce a third? As close to a control group as possible?